Cargando…
Aminoglycosides use has a risk of acute kidney injury in patients without prior chronic kidney disease
The outcome of acute kidney injury (AKI) as a result of aminoglycosides (AGs) use remains uncertain in patients without prior chronic kidney disease (CKD). Therefore, we explored the outcomes of AGs use on AKI episodes associated with renal recovery and progress in patients without prior CKD in Taiw...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568559/ https://www.ncbi.nlm.nih.gov/pubmed/36241669 http://dx.doi.org/10.1038/s41598-022-21074-x |
_version_ | 1784809665837662208 |
---|---|
author | Chou, Chu-Lin Chuang, Nai-Chen Chiu, Hui-Wen Liao, Chia-Te Hsu, Yung-Ho Chang, Tzu-Hao |
author_facet | Chou, Chu-Lin Chuang, Nai-Chen Chiu, Hui-Wen Liao, Chia-Te Hsu, Yung-Ho Chang, Tzu-Hao |
author_sort | Chou, Chu-Lin |
collection | PubMed |
description | The outcome of acute kidney injury (AKI) as a result of aminoglycosides (AGs) use remains uncertain in patients without prior chronic kidney disease (CKD). Therefore, we explored the outcomes of AGs use on AKI episodes associated with renal recovery and progress in patients without prior CKD in Taiwan. This was a retrospective cohort study by using the Taipei Medical University Research Database from January 2008 to December 2019. 43,259 individuals without CKD who had received parenteral AGs were enrolled. The exposed and unexposed groups underwent propensity score matching for age, gender, patients in intensive care unit/emergency admission, and covariates, except serum hemoglobin and albumin levels. We identified an exposed group of 40,547 patients who used AGs (median age, 54.4 years; 44.3% male) and an unexposed group of 40,547 patients without AG use (median age, 55.7 years; 45.5% male). There was the risk for AKI stage 1 (adjusted hazard ratio [HR] 1.34; 95% confidence interval [CI] 1.00–1.79; p = 0.05) in patients that used AGs in comparison with the control subjects. Moreover, patients using AGs were significantly associated neither with the progression to acute kidney disease (AKD) stages nor with the progression to end-stage renal disease (ESRD) on dialysis. Further analyzed, there was an increased risk of AKI episodes for serum albumin levels less than 3.0 g/dL and hemoglobin levels less than 11.6 g/dL. Among patients without prior CKD, AGs-used individuals were associated with AKI risks, especially those at relatively low albumin (< 3.0 g/dL) or low hemoglobin (< 11.6 g/dL). That could raise awareness of AGs prescription in those patients in clinical practice. |
format | Online Article Text |
id | pubmed-9568559 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-95685592022-10-16 Aminoglycosides use has a risk of acute kidney injury in patients without prior chronic kidney disease Chou, Chu-Lin Chuang, Nai-Chen Chiu, Hui-Wen Liao, Chia-Te Hsu, Yung-Ho Chang, Tzu-Hao Sci Rep Article The outcome of acute kidney injury (AKI) as a result of aminoglycosides (AGs) use remains uncertain in patients without prior chronic kidney disease (CKD). Therefore, we explored the outcomes of AGs use on AKI episodes associated with renal recovery and progress in patients without prior CKD in Taiwan. This was a retrospective cohort study by using the Taipei Medical University Research Database from January 2008 to December 2019. 43,259 individuals without CKD who had received parenteral AGs were enrolled. The exposed and unexposed groups underwent propensity score matching for age, gender, patients in intensive care unit/emergency admission, and covariates, except serum hemoglobin and albumin levels. We identified an exposed group of 40,547 patients who used AGs (median age, 54.4 years; 44.3% male) and an unexposed group of 40,547 patients without AG use (median age, 55.7 years; 45.5% male). There was the risk for AKI stage 1 (adjusted hazard ratio [HR] 1.34; 95% confidence interval [CI] 1.00–1.79; p = 0.05) in patients that used AGs in comparison with the control subjects. Moreover, patients using AGs were significantly associated neither with the progression to acute kidney disease (AKD) stages nor with the progression to end-stage renal disease (ESRD) on dialysis. Further analyzed, there was an increased risk of AKI episodes for serum albumin levels less than 3.0 g/dL and hemoglobin levels less than 11.6 g/dL. Among patients without prior CKD, AGs-used individuals were associated with AKI risks, especially those at relatively low albumin (< 3.0 g/dL) or low hemoglobin (< 11.6 g/dL). That could raise awareness of AGs prescription in those patients in clinical practice. Nature Publishing Group UK 2022-10-14 /pmc/articles/PMC9568559/ /pubmed/36241669 http://dx.doi.org/10.1038/s41598-022-21074-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Chou, Chu-Lin Chuang, Nai-Chen Chiu, Hui-Wen Liao, Chia-Te Hsu, Yung-Ho Chang, Tzu-Hao Aminoglycosides use has a risk of acute kidney injury in patients without prior chronic kidney disease |
title | Aminoglycosides use has a risk of acute kidney injury in patients without prior chronic kidney disease |
title_full | Aminoglycosides use has a risk of acute kidney injury in patients without prior chronic kidney disease |
title_fullStr | Aminoglycosides use has a risk of acute kidney injury in patients without prior chronic kidney disease |
title_full_unstemmed | Aminoglycosides use has a risk of acute kidney injury in patients without prior chronic kidney disease |
title_short | Aminoglycosides use has a risk of acute kidney injury in patients without prior chronic kidney disease |
title_sort | aminoglycosides use has a risk of acute kidney injury in patients without prior chronic kidney disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568559/ https://www.ncbi.nlm.nih.gov/pubmed/36241669 http://dx.doi.org/10.1038/s41598-022-21074-x |
work_keys_str_mv | AT chouchulin aminoglycosidesusehasariskofacutekidneyinjuryinpatientswithoutpriorchronickidneydisease AT chuangnaichen aminoglycosidesusehasariskofacutekidneyinjuryinpatientswithoutpriorchronickidneydisease AT chiuhuiwen aminoglycosidesusehasariskofacutekidneyinjuryinpatientswithoutpriorchronickidneydisease AT liaochiate aminoglycosidesusehasariskofacutekidneyinjuryinpatientswithoutpriorchronickidneydisease AT hsuyungho aminoglycosidesusehasariskofacutekidneyinjuryinpatientswithoutpriorchronickidneydisease AT changtzuhao aminoglycosidesusehasariskofacutekidneyinjuryinpatientswithoutpriorchronickidneydisease |